"The mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man."@en . . . "26171-23-3"@en . "Tolmetino"@en . . "Tolmetin"@en . . "Tolmetin"@en . "Tolmetina"@en . . . . . . . "A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]"@en . . . " "@en . . . . "approved"@en . . . . . . "Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain."@en . . . . . . . "For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis."@en . . . . "1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid"@en . . "Humans and other mammals"@en . . "Tolm\u00E9tine"@en . "Biphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours."@en . . . . . " "@en . . "Tolmetinum"@en . "Rapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose."@en . . . . . . . . . . . . . . . . . "5-(P-Toluoyl)-1-methylpyrrole-2-acetic acid"@en . . . . . . . . . . . . . . . . . . . . . . "1-Methyl-5-P-toluoylpyrrole-2-acetic acid"@en . . . . .